Advances in the Development of Antiviral Drugs for Ebola Virus
/ 0
- Details
- Category: Vol. 85, December 2017
- Hits: 92
Advances in the Development of Antiviral Drugs for Ebola Virus
Abstract
Aim: This study aims to provide a comprehensive overview of the Ebola virus (EBOV), focusing on its pathogenesis, trans-mission, and current strategies for treatment and prevention. Methods: The research examines the historical context of EBOV, its structural characteristics, and its interaction with the host immune system. Various vaccine and therapeutic ap-proaches, including monoclonal antibodies, vector-based vac-cines, and plant-derived antibodies, are analyzed through a re-view of existing literature and clinical trials. Results: EBOV’s high mortality rates and ability to evade the immune system highlight the urgent need for effective in-terventions. Current treatments focus on supportive care, while ongoing research is directed toward developing vaccines and therapeutics. Several promising vaccine candidates, such as rVSV-based vaccines, have shown efficacy in preclinical and
clinical trials. Monoclonal antibody therapies like ZMapp have demonstrated potential in reducing morbidity and mortality in non-human primates and humans. Conclusion: Despite significant advancements in under-standing EBOV and developing potential treatments, no fully approved vaccines or direct-acting antivirals are currently available. Continued research is crucial to develop robust, long-lasting vaccines and effective therapeutic strategies to combat EBOV, particularly in high-risk areas